- ENHERTU plus pertuzumab shows significant improvement in progression-free survival for HER2 positive metastatic breast cancer.
- The trial is the first in over a decade to surpass the current first-line treatment's efficacy.
- Regulatory submissions for ENHERTU combination therapy are underway.
AstraZeneca (AZN, Financial) and Daiichi Sankyo have announced breakthrough results from the phase 3 DESTINY-Breast09 trial, showcasing that their drug combination, ENHERTU plus pertuzumab, provides a highly statistically significant and clinically meaningful improvement in progression-free survival for patients with HER2 positive metastatic breast cancer. This combination therapy outperformed the current standard first-line treatment, marking the first superior efficacy result in over a decade.
HER2 positive metastatic breast cancer, affecting 15% to 20% of metastatic breast cancer patients, poses a significant treatment challenge as most patients experience disease progression within two years of first-line therapy. The promising results from the DESTINY-Breast09 trial address this need by potentially delaying disease progression, offering patients a chance for better outcomes.
The safety profile of the ENHERTU combination was consistent with established profiles of each therapy involved, hinting at a manageable toxicity level. While overall survival data remains immature, early trends are favorable for the ENHERTU combination, suggesting potential long-term survival benefits.
With these results, AstraZeneca and Daiichi Sankyo are preparing regulatory submissions, aiming to introduce this new therapeutic option to the market and redefine the treatment paradigm for HER2 positive metastatic breast cancer.
